newsfilter
← Latest News
PR Newswire·

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

SAN DIEGO, Aug. 7, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipeline, today reported